What Is Medetomidine? Pennsylvania’s Newest Drug Supply Threat
What Is Medetomidine and Why Is It Now in Pennsylvania’s Drug Supply?
If you have been following news about the opioid crisis in Pennsylvania, you may have heard about xylazine, the veterinary sedative known as “tranq” that became widely mixed into the fentanyl supply in Philadelphia and surrounding communities. Xylazine made an already dangerous drug supply even more unpredictable and harder to treat. But the drug supply in Pennsylvania has shifted again, and the substance now showing up in the majority of fentanyl samples is something even less understood: medetomidine.
Medetomidine is a synthetic sedative approved by the FDA for use in dogs and cats. It is not approved for use in humans under any circumstances. Like xylazine, it belongs to a class of drugs called alpha-2 adrenoreceptor agonists, meaning it works on the central nervous system to slow brain activity, lower heart rate, and suppress breathing. Unlike xylazine, medetomidine is estimated to be anywhere from 100 to 300 times more potent, making its presence in Pennsylvania’s illicit drug supply an urgent public health concern.
Drug suppliers began mixing medetomidine into fentanyl for the same reason they used xylazine: it is cheap, extends the drug supply, and intensifies sedation, which makes the product more appealing to people already dependent on opioids. What users are almost never aware of is that they are taking it at all.
How Medetomidine Took Over Pennsylvania’s Drug Supply So Quickly
The speed at which medetomidine spread through Pennsylvania’s drug supply is alarming. Medetomidine was first detected in street-level drugs in Maryland in 2022 and gradually began appearing in Pennsylvania shortly after. When Philadelphia health officials began formally testing for it in May 2024, they found it in 29 percent of fentanyl samples. Just six months later, that figure had risen to 87 percent.
The timing was not coincidental. In May 2024, Governor Josh Shapiro permanently classified xylazine as a Schedule III controlled substance in Pennsylvania, tightening restrictions on the drug that had previously been used freely as a cutting agent. Within months, medetomidine had largely replaced xylazine in the Philadelphia drug supply. By the final months of 2024, medetomidine was detected in 72 percent of illegal opioid samples tested in Philadelphia, while xylazine detection dropped from 98 percent to just 31 percent over the same period.
The pattern illustrates a troubling dynamic in the modern drug supply: when one dangerous adulterant is restricted, suppliers quickly adapt by substituting another. Medetomidine has now been identified in samples from multiple counties across Pennsylvania, including in Pittsburgh, where a cluster of severe withdrawal cases was documented at area hospitals between October 2024 and March 2025.
Why Medetomidine Makes Overdoses More Dangerous and Harder to Reverse
Families of people who use drugs in Pennsylvania need to understand how medetomidine changes the overdose picture in important and potentially life-threatening ways.
For years, Pennsylvania communities have been educated about naloxone, the opioid reversal medication sold under the brand name Narcan. Naloxone works by blocking opioid receptors in the brain, rapidly reversing the respiratory depression that makes fentanyl overdoses fatal. It has saved countless lives across the state.
Medetomidine is not an opioid. Because it works through a completely different receptor system, naloxone cannot reverse its effects. A person overdosing on fentanyl mixed with medetomidine may not respond the way someone would after a typical opioid overdose. They may remain deeply sedated and unresponsive even after receiving naloxone, leading bystanders and even first responders to believe the naloxone is not working or to administer more doses than is safe.
Public health officials are now advising that overdose response for suspected medetomidine-involved overdoses should focus primarily on breathing rather than on whether the person becomes responsive. Keeping the airway open and performing rescue breathing are critical because the sedation from medetomidine can persist even after the fentanyl component has been addressed.
Experts still recommend administering naloxone immediately if an overdose is suspected, because fentanyl is present in virtually all medetomidine-involved overdoses. However, administering too much naloxone carries its own risk: it can trigger precipitated withdrawal, which in the context of medetomidine can be severe and dangerous. Lower dose naloxone products are preferred when available, and calling 911 immediately is essential.
The Signs of a Medetomidine-Involved Overdose
Because medetomidine produces effects similar to opioid overdose on the surface, it can be difficult to distinguish without testing. Families and bystanders should be aware of the following warning signs:
- Extreme sedation or unresponsiveness
- Very slow or stopped breathing
- Slow heart rate (bradycardia)
- Blue or grayish skin, especially around the lips and fingernails
- Persistent unresponsiveness even after naloxone has been administered
- Rapidly shifting vital signs, swinging between dangerously low and dangerously high blood pressure
The last sign points to one of the most serious aspects of medetomidine: its withdrawal syndrome. When the drug begins to wear off, the body can swing dramatically from the suppression caused by the drug to a state of severe overactivation, with dangerous spikes in blood pressure and heart rate. This can happen quickly, sometimes within hours of last use.
Medetomidine Withdrawal Is a Medical Emergency
One of the most important things families in Pennsylvania need to understand is that withdrawal from fentanyl mixed with medetomidine is not like standard opioid withdrawal. Standard opioid withdrawal is deeply uncomfortable and distressing, but it is rarely life-threatening in otherwise healthy adults. Medetomidine withdrawal is different.
Between September 2024 and January 2025, 165 patients were hospitalized across three Philadelphia health systems with a previously unrecognized withdrawal syndrome linked to medetomidine. The vast majority required intensive care unit level treatment. Nearly a quarter needed to be intubated. Standard opioid and xylazine withdrawal medications did not work. The syndrome was characterized by profound autonomic dysfunction, including severe hypertension, rapid heart rate, uncontrollable vomiting, tremor, and fluctuating altered mental status.
A similar pattern was documented in Pittsburgh between October 2024 and March 2025, where 23 patients at two hospitals experienced severe autonomic hyperactivity after stopping illegally manufactured opioid use. Most required ICU care and treatment with dexmedetomidine, a related drug used in critical care settings that proved effective in stabilizing the withdrawal syndrome.
Medetomidine withdrawal symptoms can begin abruptly within hours of last use, peaking between 18 and 36 hours. Anyone who is dependent on fentanyl in Pennsylvania should be considered at risk for medetomidine withdrawal given how widespread it has become in the drug supply. Attempting to stop using at home without medical supervision is not safe.
How Medetomidine Differs from Xylazine: What Pennsylvania Families Should Know
Families who learned about xylazine and tranq dope may be wondering how medetomidine compares. There are important similarities and some key differences.
Both are veterinary sedatives not approved for human use. Both are mixed into fentanyl by suppliers. Both produce sedation that naloxone cannot fully reverse, and both carry serious withdrawal risks. These similarities mean many of the harm reduction lessons from the xylazine crisis still apply.
The main differences involve potency and wound effects. Medetomidine is dramatically more potent than xylazine, which means even small amounts can have serious effects. On a more positive note, surveillance data from Philadelphia suggests that medetomidine does not appear to cause the severe skin wounds and ulcers that were a hallmark of xylazine use. Presentations for substance use-related wounds at Philadelphia hospitals have decreased by nearly 50 percent since medetomidine became dominant in the drug supply, suggesting the wound crisis associated with tranq dope may be easing even as a new threat has emerged.
However, the shift to medetomidine should not be read as good news overall. A drug that is far more potent, produces overdoses that are harder to reverse, and causes life-threatening withdrawal is a serious escalation in the dangers facing people who use drugs in Pennsylvania.
What Families in Pennsylvania Can Do Right Now
Carry naloxone and know how to use it. Naloxone is available without a prescription at pharmacies across Pennsylvania. Even though it cannot reverse medetomidine’s effects directly, it remains essential because fentanyl is present in virtually every medetomidine-involved overdose. When responding to a suspected overdose, administer naloxone and focus on keeping the person breathing while waiting for emergency services.
Call 911 immediately. Medetomidine-involved overdoses require emergency medical care. Pennsylvania’s Good Samaritan Law protects people who call for help during an overdose from drug-related prosecution, so do not hesitate to call.
Do not assume an overdose has been fully reversed. If someone remains unresponsive or heavily sedated after receiving naloxone, this may indicate medetomidine is involved. Keep them in the recovery position, continue monitoring their breathing, and stay with them until emergency services arrive.
Understand that withdrawal requires medical supervision. If your loved one wants to stop using fentanyl, they need professional medical support before doing so. Given how widely medetomidine has spread through Pennsylvania’s drug supply, any attempt to detox at home carries serious risk.
Ask about medetomidine test strips. The Philadelphia Department of Public Health has begun distributing medetomidine test strips through community-based organizations. These can help people who use drugs know what is in their supply, though they are not a substitute for treatment.
Addiction Treatment for Fentanyl Use Disorder in Pennsylvania
At High Focus Centers in Pennsylvania, we understand that the drug supply our community is navigating today is more dangerous and more complicated than it has ever been. People dependent on fentanyl in Pennsylvania are often unknowingly using a drug mixed with one or more powerful veterinary sedatives, and getting safe from this requires medical support and evidence-based care.
Our Partial Hospitalization Programs (PHP) and Intensive Outpatient Programs (IOP) provide structured treatment for adults and adolescents dealing with opioid use disorder and co-occurring mental health conditions. We offer medication-assisted treatment (MAT) and connect individuals with the level of medical support their withdrawal and recovery needs require.
If your loved one is struggling with fentanyl use in Pennsylvania, the time to reach out is now. The drug supply is not getting simpler or safer, and professional treatment makes a life-changing difference.
Pennsylvania Resources for Opioid Use Disorder
PA Get Help Now Hotline: 1-800-662-HELP (4357), available 24 hours a day to connect callers with local treatment resources.
Pennsylvania DDAP Treatment Locator: ddap.pa.gov provides a searchable directory of treatment providers across the state.
Naloxone Access in PA: Available without a prescription at pharmacies statewide. Also available through harm reduction organizations and community health programs.
High Focus Centers Pennsylvania: Contact us directly to learn about our outpatient programs and how we can help your family.
